The pathophysiology of overactive bladder (OAB) is multifactorial. Although, the two pivotal myogenic (alterations in bladder smooth muscle contractility and excitability) and neurogenic (increased or sensitized sensory transmission, abnormalities in spinal and supraspinal control) basis for the OAB development have been proposed (4, 8, 28). The neurogenic theory explains that the backgrounds for OAB seems to be partially related to alterations in bladder afferent nerve fibres localized within the bladder mucosa. Animal studies revealed that the bladder mucosa is characterized by a significantly lower concentration of high-energy phosphates and higher oxidative metabolic rate than the detrusor smooth muscle. This facts point that the bladder mucosa is significantly more sensitive to anoxia than is the bladder smooth muscle (13, 18). Azadzoi et al. (2) study revealed that long-term arterial insufficiency leads to bladder neuropathy via ischemia, hypoxia and oxidative stress. OAB under the ischemic condition generates neurotoxic oxidative and nitrosative products. Neurodegeneration is postulated to be an end stage phenomenon in ischemia induced bladder overactivity. The increased sensitivity of urothelium to different stimuli (e.g. hypoxia, ischemia, hyperosmotic agents, etc.) would indicate that bladder afferents (pain, altered sensations, reflex contractions) might be activated at levels of hypoxia/ischemia that have no direct effect on bladder smooth muscle function. Therefore, a novel strategies for therapeutic approach of OAB based: 1) reducing the phasic increase in intracellular calcium that causes the activation of calcium activated hydrolytic enzymes, 2) stabilizing the neuronal or smooth muscle membrane components that are hydrolyzed by the activated enzymes; or 3) employing free radical scavengers that reduce the activation of cellular lipid peroxidases and the reperfusion injury, seem to be crucial (19).

Introduction

The pathophysiology of overactive bladder (OAB) is multifactorial. Although, the two pivotal myogenic (alterations in bladder smooth muscle contractility and excitability) and neurogenic (increased or sensitized sensory transmission, abnormalities in spinal and supraspinal control) basis for the OAB development have been proposed (4, 8, 28). The neurogenic theory explains that the backgrounds for OAB seems to be partially related to alterations in bladder afferent nerve fibres localized within the bladder mucosa.

Animal studies revealed that the bladder mucosa is characterized by a significantly lower concentration of high-energy phosphates and higher oxidative metabolic rate than the detrusor smooth muscle. This facts point that the bladder mucosa is significantly more sensitive to anoxia than is the bladder smooth muscle (13, 18). Azadzoi et al. (2) study revealed that long-term arterial insufficiency leads to bladder neuropathy via ischemia, hypoxia and oxidative stress. OAB under the ischemic condition generates neurotoxic oxidative and nitrosative products. Neurodegeneration is postulated to be an end stage phenomenon in ischemia induced bladder overactivity. The increased sensitivity of urothelium to different stimuli (e.g. hypoxia, ischemia, hyperosmotic agents, etc.) would indicate that bladder afferents (pain, altered sensations, reflex contractions) might be activated at levels of hypoxia/ischemia that have no direct effect on bladder smooth muscle function.

Summary: This study was designed to investigate the effects of melatonin on the bladder hyperactivity in hyperosmolar-induced overactive bladder (OAB) rats. Additionally, the influence of melatonin on the autonomic nervous system (ANS) using heart rate variability (HRV) analysis was assessed. 40 rats were divided into four groups: I - control (n=12), II - rats with hyperosmolar OAB (n=6), III - rats with melatonin pretreatment and hyperosmolar OAB (n=6) and IV - control with melatonin pretreatment (n=6). In group III and IV melatonin in dose of 100 mg/kg was given. HRV measurement in 10 rats, as follow: control (n=2), control after melatonin treatment (n=2), rats with hyperosmolar OAB without (n=3), and after (n=3) melatonin treatment were conducted. This study demonstrates marked influence of melatonin on urinary bladder activity in hyperosmolar-induced OAB rats. These rats showed significantly reduced the detrusor motor overactivity resulting in the improvement of cystometric parameters after melatonin treatment when compared to the control, as follow: a significant increase of intercontraction interval (70 %) and functional bladder capacity (67 %), as well as a decrease of the basal pressure, detrusor overactivity index and motility index of 96 %, 439 % and 40 %, respectively. ANS activity analysis revealed sympathetic overactivity in OAB rats, and parasympathetic superiority in melatonin treated OAB rats. Melatonin treatment in rats with hyperosmolar OAB (group III) caused significant increase of nuHF parameter (from 51.00 ± 25.29 to 76.97 ± 17.43), as well as a decrease of nuLF parameter (from 49.01 ± 25.26 to 23.03 ± 17.43) and LF/HF ratio (from 1.280 ± 0.980 to 0.350 ± 0.330). In conclusion, melatonin suppresses hyperosmolar OAB, and modulates ANS activity by inhibition of the sympathetic drive. Therefore, melatonin may become a useful agent for OAB management.

Key words: Melatonin; Hyperosmolarity; Overactive bladder; Cystometry; Rats; Heart rate variability; Autonomic nervous system
act as antioxidant and cytoprotective agents by reducing the oxidative stress directly by acting as a free radical scavenger (30), and also by activating several antioxidant systems (31). Also, some papers described that autonomic nervous system (ANS) in patients with overactive bladder is altered and may be a factor in disturbed bladder function (7). Melatonin’s influence on peripheral receptors may be triggered due to the alterations in autonomic activity, connected with the inhibition of the sympathetic branch of the ANS.

Purpose

This study was designed to investigate the protective effect of melatonin against hyperosmolar-induced urinary bladder overactivity in rats. Additionally, the influence of exogenous melatonin on the autonomic nervous system activity using heart rate variability recording was assessed.

Material and methods

Animals. The study was performed on forty adult female Wistar rats (weight: 200–275 g). Rats were housed individually per cage. The animal room was maintained at a constant temperature of 23 °C, humidity and a 12:12 h alternating light-dark cycle. They were fed with animal’s food (Labofeed; Kcyinia, Poland) with any restraint to water. The study has been approved by the Regional Animals Ethical Committee.

Hyperosmolar model of overactive bladder in rats. The bladder overactivity was induced by constant intravesical infusion of hyperosmolar solution of saline of its concentration at 2080 mOsm/l and at a rate of 0.046 ml/min. They were fed with animal’s food (Labofeed; Kcyinia, Poland) with any restraint to water. The study has been approved by the Regional Animals Ethical Committee.

Surgical procedure. Bladder catheter implantation: under urethane anaesthesia with intraperitoneal injection of 1.2 g/kg urethane (Sigma-Aldrich, Germany) in dose of 100 mg/kg was given intraperitoneally (1 ml of melatonin solution) after catheter implantation within 20 minutes before hyperosmolar or isotonic saline infusion, respectively.

The measurements in each animal represent the average of five bladder micturition cycles, after obtaining repetitive voiding. The following cystometrogram’s (CMGs) parameters were recorded: BP – basal pressure (cmH₂O), PT – threshold pressure (cmH₂O), MVP – micturition voiding pressure (cmH₂O), ICI – intercontraction interval (min.), Compliance (ml/cmH₂O), fBC – functional bladder capacity (ml). Moreover we calculated MI – motility index (cmH₂O x s/min.) in 10-minutes intervals. In addiction we analysed DI – detrusor index (cmH₂O/ml) in group I and DOI – detrusor overactivity index (cmH₂O/ml) in other groups, depicted as quotient of the sum of amplitudes of all detrusor contractions during filling phase and functional bladder capacity (1).

The “sham” group for group III (rats with melatonin pretreatment and hyperosmolar OAB) and IV (control group with melatonin pretreatment) were also tested. We revealed no significantly changes in CMG and HRV parameters in rats with hyperosmolar OAB + saline i.p., pre-treatment (control to group III), as well as in case of control rats with saline i.p. pre-treatment (control to group IV). Therefore, we detailed description of these results was omitted.

HRV studies. The experimental procedures were conducted by using heart rate variability (HRV) measurements in 10 female Wistar rats, as follow: control rats (n=2), control rats after melatonin treatment (n=2), rats with hyperosmolar OAB (n=3), and rats with hyperosmolar OAB after melatonin treatment (n=3). To the HRV analysis there was used PowerLab (ADInstruments, Australia) set. 10-minutes intervals of ECG recording were analysed for HRV and ANS activity estimation. The following HRV parameters were taken into consideration: mRR (ms), HR (BPM), SDNN (ms), RMSSD (ms), VLF (ms²) – power of very low frequency (0.0033–0.04 Hz), LF (ms²) – power of low frequency (0.04–0.15 Hz), LFnu ( %) – LF power in normalized units LF/(TP – VLF) x 100, HF (ms²) – power of high frequency (0.15–0.4 Hz), HFnu ( %) – HF power in normalized units HF/(TP – VLF) x 100, LF/HF – ratio of LF power to HF power, LF/HFnu ( %) – normalized ratio of LF power to HF power, PSD (TP) (ms⁴) – total power of spectrum of the RR variability. Normalized units are used to emphasize the reciprocal action of the parasympathetic and sympathetic limbs of ANS and to minimize the effect of changes in total power on the values of LF and HF components (17). The HRV parameters were analyzed using software application Chart Pro 5.

Study protocol. All animals were randomly divided into four groups: group I – control group (n=12), group II – rats with hyperosmolar OAB (n=6), group III – rats with melatonin pretreatment and hyperosmolar OAB (n=6) and group IV – control group with melatonin pretreatment (n=6). Cystometry was performed 1h after surgical procedure in all groups. In group III and IV melatonin (Sigma-Aldrich, Germany) in dose of 100 mg/kg was given intraperitoneally (1 ml of melatonin solution) after catheter implantation within 20 minutes before hyperosmolar or isotonic saline infusion, respectively.
Tab. 1: Cystometrogram’s parameters in normal rats (group I), in hyperosmolar OAB rats without and after melatonin treatment (group II and III, respectively) and in normal rats after melatonin treatment (group IV).

<table>
<thead>
<tr>
<th></th>
<th>Group I: CONTROL</th>
<th>Group II: 2080 mOsm/l NaCl</th>
<th>Group III: 2080 mOsm/l NaCl + MELATONIN</th>
<th>Group IV: CONTROL + MELATONIN</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP (cmH₂O)</td>
<td>1.41 ± 0.60</td>
<td>3.07 ± 0.16</td>
<td>1.57 ± 0.17</td>
<td>1.48 ± 0.30</td>
<td>0.000</td>
</tr>
<tr>
<td>PT (cmH₂O)</td>
<td>5.70 ± 1.22</td>
<td>6.12 ± 0.26</td>
<td>5.42 ± 0.67</td>
<td>5.53 ± 0.70</td>
<td>NS</td>
</tr>
<tr>
<td>MVP (cmH₂O)</td>
<td>27.4 ± 4.9</td>
<td>25.9 ± 4.9</td>
<td>22.4 ± 3.4</td>
<td>27.6 ± 3.2</td>
<td>NS</td>
</tr>
<tr>
<td>ICI (min.)</td>
<td>5.28 ± 1.55</td>
<td>2.59 ± 0.26</td>
<td>4.40 ± 0.87</td>
<td>5.27 ± 0.84</td>
<td>0.001</td>
</tr>
<tr>
<td>Compliance (ml/cmH₂O)</td>
<td>0.059 ± 0.019</td>
<td>0.040 ± 0.008</td>
<td>0.054 ± 0.013</td>
<td>0.062 ± 0.013</td>
<td>NS</td>
</tr>
<tr>
<td>fBC (ml)</td>
<td>0.240 ± 0.070</td>
<td>0.120 ± 0.012</td>
<td>0.200 ± 0.040</td>
<td>0.243 ± 0.039</td>
<td>0.001</td>
</tr>
<tr>
<td>DI/DOI (cmH₂O/ml)</td>
<td>121.9 ± 33</td>
<td>625.8 ± 101.4</td>
<td>116.1 ± 32.0</td>
<td>129.6 ± 24.8</td>
<td>0.000</td>
</tr>
<tr>
<td>MI (cmH₂O x s/min.)</td>
<td>185.4 ± 45.9</td>
<td>245.2 ± 61.5</td>
<td>180.3 ± 45.5</td>
<td>164.7 ± 31.5</td>
<td>0.007</td>
</tr>
</tbody>
</table>

*group II versus group I; #group II versus group III

Fig. 1: Cystometrogram’s traces in control and with hyperosmolar OAB rats with and without melatonin treatment. The figure shows 20-minutes interval (horizontal axis). Vertical axis estimates intravesical pressure of (-5)–40 cmH₂O range.

Fig. 2: The percentage of significantly changes of basal pressure (BP), intercontraction interval (ICI), functional bladder capacity (fBC), detrusor overactivity index (DOI) and motility index (MI) in rats with hyperosmolar OAB (group II) compared to normal, healthy rats (group I) and to rats with hyperosmolar OAB with melatonin treatment (group III).
Statistical analysis. The results are expressed as mean and standard deviation (± SD). Shapiro-Wilk tests were used to test for normal distribution of the data. A Kruskal-Wallis test was utilized for multiple comparisons. Mann-Whitney U tests were used for post-hoc comparisons with Bonferroni correction of the alpha in order to maintain the overall probability of a type I error at 0.05. For HRV parameters values analysis the test T-students was used. A p value of <0.05 was considered significant. The data were analyzed with SPSS software (version 12.0).

Results

Effect of hyperosmolar saline intravesical infusion on bladder motor activity – hyperosmolar model of overactive bladder. The hyperosmolar saline (2080 mOsm/l) intravesical infusion induced bladder motor overactivity. The cystometric curve was similar to the recordings of bladder activity after chemical induction of OAB using cyclophosphamide in acute model (11). We observed a significant decrease of intercontraction intervals (104 %) and functional bladder capacity (100 %). Also an increase of basal pressure (118 %), detrusor activity (413 %) and motility index (33 %) were observed (Tab. 1, Fig. 1, Fig. 2). No statistically differences of threshold, micturition voiding pressure and compliance were obtained.

Effect of melatonin on bladder motor activity in hyperosmolar overactive bladder rats. Intraperitoneally administration of 100 mg/kg melatonin reduced the detrusor motor overactivity resulting in the improvement of cystometric parameters in hyperosmolar overactive bladder rats. In comparison to hyperosmolar overactive bladder rats, we recorded significantly increase of intercontraction interval (70 %) and functional bladder capacity (67 %). The basal pressure, detrusor overactivity index and motility index significantly decreased of 96 %, 439 % and 40 %, respectively. The threshold and maximal voiding pressure, compliance were not significantly changed (Tab. 1, Fig. 1, Fig. 2).

Effect of melatonin on bladder motor activity in normal, healthy rats. The melatonin given intraperitonealy in 100 mg/kg dose revealed no distinctive impact on urinary bladder function in normal, healthy rats (Tab. 1, Fig. 1, Fig. 2).

Effect of melatonin on autonomic nervous system (ANS) activity in normal and with hyperosmolar overactive bladder rats. In control group (group I) the intensified activity of parasympathetic branch of ANS occurred. It was characterized by LF/HF ratio values (0.085 ± 0.100) and increased values of nuHF parameter (mean: 92.75 ± 8.36) in comparison with nuLF parameter (mean: 16.88 ± 12.92).

In rats with hyperosmolar OAB significant increase of LF parameter (from 0.095 ± 0.100 to 0.230 ± 0.070; p = 0.019), and LF/HF ratio (from 0.085 ± 0.100 to 0.579 ± 0.583; p=0.076), as well as a decrease of nuHF parameter (from 92.75 ± 8.36 to 70.43 ± 25.55; p=0.065). Additionally, HRV analysis of two different intervals of ECG recordings (between 5–15 minutes and 25–35 minutes after hyperosmolar saline intravesical infusion) revealed the slight differences of HRV parameters in the following intervals characterized by decrement of LF parameter values (from 0.230 ± 0.070 to 0.124 ± 0.080; p<0.023) and SDNN parameter value (from 4.618 ± 1.730 to 2.400 ± 0.071; p = 0.026) (Fig. 3).

Melatonin treatment in rats with hyperosmolar OAB (group III) caused significant increase of nuHF parameter (from 51.00 ± 25.29 to 76.97 ± 17.43), as well as a decrease of nuLF parameter (from 49.01 ± 25.26 to 23.03 ± 17.43) and LF/HF ratio (from 1.280 ± 0.980 to 0.350 ± 0.330) (Fig. 3). The HRV analysis of two different intervals of ECG recordings (between 5–15 minutes and 25–35 minutes after melatonin administration and hypertonic – group III saline intravesical infusion) revealed no differences of HRV parameters in the following intervals.

Also no significant changes of HRV parameters were observed in the two following intervals of ECG recordings (between 0–10 minutes and 10–20 minutes after melatonin administration and isotonic – group IV saline intravesical infusion).
Discussion

The results of the current experiment show that melatonin has protective impact on hyperosmolar-induced urinary bladder overactivity (OAB) in rats. One of the theory of OAB development is based on the formation of Reactive Oxygen Species (ROSs) in different pathophysiological condition affecting proper urinary bladder function (e.g. bladder outlet obstruction, ischaemia/reperfusion and inflammation processes) (5, 10, 20). ROSs lead to lipid peroxidation of cellular membranes altering its function (27). The changed cells membrane properties cause the increased excitability of both neuronal and smooth muscle membranes, which directly results in OAB. The loss of lipids in specific cellular membranes can result in denervation, denervation supersensitivity (increased sensitivity of the autonomic receptors to neurohumoral transmission), increased sensitivity of the smooth muscle membrane to myogenic stimulation, and induction of both neurogenic and myogenic overactivity (19).

Melatonin is originally defined as a agent which reduces lipid peroxidation and scavenges ROSs initiating lipid peroxidation (25, 29). Also, melatonin has potent antioxidative properties (3). Employing the ROSs scavengers (e.g. melatonin) that reduce the activation of cellular lipid peroxidases and secondarily bladder overactivity seems to be crucial. There are no data considering the influence of melatonin on bladder motor activity and autonomic nervous system function in healthy and hyperosmolar-induced OAB rats (in vivo). Therefore, based on these facts we established the experiment to determine whether melatonin ameliorates the bladder hyperactivity in hyperosmolar-induced OAB rats.

This study demonstrates marked influence of intraperitoneally administration of melatonin in 100 mg/kg dose on urinary bladder activity in hyperosmolar-induced OAB in rats. The rats with hyperosmolar-induced OAB in this experiment showed significantly reduced the detrusor motor overactivity resulting in the improvement of cystometric parameters after melatonin treatment when compared to the control OAB group. After melatonin treatment the OAB rats revealed significantly decrease of intercontraction interval (70 %) and functional bladder capacity (67 %). The basal pressure, detrusor overactivity index and motility index significantly decreased of 96 %, 439 % and 40 %, respective-ly. The distinctive decrease of detrusor overactivity index is caused by inhibition of the non-voiding contractions (NVCs) and elongation of intercontraction intervals after melatonin administration. The symptoms of OAB are usually attributed to involuntary contractions of the detrusor muscle, as well as the severity of OAB symptoms defines the grade of bladder overactivity, which partly depends on the profile of non-voiding and micturition-voiding induced contractions (14, 23). Thus, melatonin seems to be a novel agent reducing OAB symptoms.

Although the exact pathomechanism of melatonin action within the urinary tracts has not yet been elucidated, the ameliorating effects of melatonin on urinary bladder overactivity represent a novel pathway in the pharmacological treatment of OAB. Based on the results of different studies, the potential mechanism of melatonin action in OAB rats can be taken under the consideration. Firstly, hyperosmolar saline given intravesically can penetrate submucosal layers of urinary bladder and activates capsaicin-sensitive C neurons and consequently induce neurogenic inflammation leading to OAB (15). Masuda et al. (22) revealed that ROSs, especially H₂O₂ and -OH, might stimulate capsaicin-sensitive bladder afferent fibres, thereby inducing detrusor overactivity in rats. Thus, the possible mechanism seems to be concerned with C-fibres activity, which relays on scavenge of ROSs by melatonin, in result reducing the afferent C-fibres activity and secondarily the urinary bladder hyperactivity. Secondarily, Semercioz et al. (26) considered the other possible mechanisms of melatonin induced inhibition of urinary bladder contractility may be its interaction with calmodulin or its calcium-channel blocking effects. They observed that melatonin inhibits acetylcholine and KCl-induced contractions in isolated bladder strips from guinea pigs. Melatonin can bind to Ca²⁺-activated calmodulin with high affinity, and may prevent it from activating myosin light-chain kinase, leading to decreased contractility (24). Moreover, Gomez-Pinilla et al. (11) obtained that melatonin treatment restored smooth muscle contractility by normalizing Ca²⁺ signalling and increasing Ca²⁺ sensitization in age-related changes in the contractility of detrusor smooth muscle. Moreover, the other possible mechanism of melatonin ameliorating action on detrusor hyperactivity is the influence of melatonin on its peripheral and central receptors (MT1 and/or MT2).

The new theory of OAB development concerning with interaction between capsaicin-sensitive bladder afferent nerves and ROSs within the bladder nerves and urothelial layer is strongly supported by the results of Chien CT et al. (5), Masuda et al. (22) and Chien WC et al. (6) experiments. They observed that exogenous substance P via NK₁-receptor activation enhances the micturition reflex and ROSs release from the inflammatory cells and leads to a OAB. Also the high dose of 3 % H₂O₂ given intravesically-ly decreased the micturition voiding pressure immediately and induced dribbling incontinence in rats. In pretreated rats with capsaicin (to achieve the desensitization of afferent C-fibres pathway) the afferent C-fibres responses to 0.3 % H₂O₂ were significantly reduced. These facts strongly suggest that capsaicin-sensitive bladder afferent fibres are important in the sensory transduction of ROSs in the urinary bladder (22).

According to neurogenic theory of bladder overactivity development, several studies suggest that one of the various pathophysiological factors responsible for OAB development seems to be a specific dysfunction of the autonomic nervous system. Our preliminary results of ANS activity assessment using HRV recording showed ANS activity disturbance. In comparison with control animals, in the ani-
mals with hypersomolar OAB the superiority of sympathetic branch ANS activity was recorded. The melatonin treatment induced ANS changes. Differentially, rats with hypersomolar OAB treated with melatonin obtained the overactivity of parasympathetic ANS drive. Study performed on humans by Hubeaux et al. (12) demonstrates the predominance of parasympathetic activity with the bladder emptied and a preponderance of sympathetic activity at the end of bladder filling in women with overactive bladder syndrome. These observations suggest dysfunction in the autonomic balance, as implied in idiopathic overactive bladder syndrome.

Thus, the OAB induced by hypersomolar saline intravesical infusion might be the result of increased ROSs release from urothelium and inflammatory cells (e.g. mastocytes) within the urinary bladder which indirectly activate the afferent capsaicin-sensitive pathway responsible for OAB development, as well as a result of autonomic nervous system imbalance. For that reason, further investigations are needed to clarify the contribution of ROSs, ANS and melatonin receptor-mediated pathways in urinary bladder function and pathomechanism of the ameliorating action of melatonin in hypersomolar-induced OAB rats.

Conclusion

In conclusion, our results revealed that melatonin suppresses increased hypersomolar-induced bladder activity, and modulates the autonomic nervous system activity by inhibition of the sympathetic drive. Therefore, melatonin may become a useful agent for OAB management.

Acknowledgments

Conflict of interests – None declared.

References